• English
    • français
  • Help
  •  | 
  • Contact
  •  | 
  • About
  •  | 
  • Login
  • HAL portal
  •  | 
  • Pages Pro
  • EN
  •  / 
  • FR
View Item 
  •   LillOA Home
  • Liste des unités
  • Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
  • View Item
  •   LillOA Home
  • Liste des unités
  • Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Prognostic factors of survival in HIV/HCV ...
  • BibTeX
  • CSV
  • Excel
  • RIS

Document type :
Article dans une revue scientifique
DOI :
10.1111/liv.13921
PMID :
29947467
Permalink :
http://hdl.handle.net/20.500.12210/4627
Title :
Prognostic factors of survival in HIV/HCV co-infected patients with hepatocellular carcinoma: The CARCINOVIC Cohort.
Author(s) :
Gelu-Simeon, Moana [Auteur]
Lewin, Maite [Auteur]
Ostos, Maria [Auteur]
Bayan, Tatiana [Auteur]
Beso Delgado, Maria [Auteur]
Teicher, Elina [Auteur]
Layese, Richard [Auteur]
Roudot-Thoraval, Francoise [Auteur]
Fontaine, Helene [Auteur]
Sobesky, Rodolphe [Auteur]
Salmon, Dominique [Auteur]
Samuel, Didier [Auteur]
Seror, Olivier [Auteur]
Nahon, Pierre [Auteur]
Meyer, Laurence [Auteur]
Duclos-Vallee, Jean-Charles [Auteur]
Journal title :
Liver international
Abbreviated title :
Liver Int.
Publication date :
2018-06-27
ISSN :
1478-3231
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
BACKGROUND & AIMS: HIV/HCV co-infected patients with hepatocellular carcinoma (HCC) have poorer survival than HCV mono-infected patients. We aimed to evaluate the prognostic factors for survival. METHODS: From 2006 to ...
Show more >
BACKGROUND & AIMS: HIV/HCV co-infected patients with hepatocellular carcinoma (HCC) have poorer survival than HCV mono-infected patients. We aimed to evaluate the prognostic factors for survival. METHODS: From 2006 to 2013, 55 incident HCCs among HIV+/HCV+ patients, from three ANRS cohorts, were compared with 181 HCCs in HIV-/HCV+ patients from the ANRS Cirvir cohort. RESULTS: HIV+/HCV+ patients were younger (50 years [IQR: 47-53] vs 62 [54-70], P < 0.001), male (89% vs 63%, P < 0.001) than HIV-/HCV+ patients. At HCC diagnosis, both groups had a majority of non-responders to anti-HCV-therapy, and HIV+/HCV+ patients had more frequently known a previous cirrhosis decompensation (31% vs 14%, P = 0.005). At diagnostic imaging, there were more infiltrative forms of HCC in HIV+/HCV+ group (24% vs 14%, P < 0.001), associated with tumour portal thrombosis in 29%. During a median follow-up period of 11.96 [5.51-27] months since HCC diagnosis, a majority of palliative treatments were decided in HIV+/HCV+ patients (51% vs 19%, P < 0.001). The 1 and 2-year crude survival rates were 61% versus 78% and 47% versus 63%, P = 0.003 respectively. In a Cox model multivariate analysis adjusted for the cohort, age and sex, the most important prognostic factor for survival was the infiltrative form of the tumour (aRR: 8.10 [4.17-15.75], P < 0.001). CONCLUSIONS: The radiological aggressiveness of the tumour is the best prognostic factor associated with poorer survival of HCC in HIV+/HCV+ patients. High alpha-foetoprotein level and decompensated cirrhosis are other ones. This justifies a particular attention to the detection and the management of small nodules in this high-risk population.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Inserm
Université de Lille
CHU Lille
Collections :
  • Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Research team(s) :
Inflammatory digestive disease : pathophysiology and therapeutic targets developement
Submission date :
2019-03-01T14:17:46Z
Université de Lille

Mentions légales
Université de Lille © 2017